These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38926722)

  • 1. Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review.
    Mahé G; Aboyans V; Cosson E; Mohammedi K; Sarlon-Bartoli G; Lanéelle D; Mirault T; Darmon P
    Cardiovasc Diabetol; 2024 Jun; 23(1):220. PubMed ID: 38926722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical and lifestyle management of peripheral arterial disease.
    Parvar SL; Fitridge R; Dawson J; Nicholls SJ
    J Vasc Surg; 2018 Nov; 68(5):1595-1606. PubMed ID: 30360849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary Medical Therapies for Patients with Peripheral Artery Disease and Concomitant Type 2 Diabetes Mellitus: a Review of Current Evidence.
    Narcisse DI; Katzenberger DR; Gutierrez JA
    Curr Cardiol Rep; 2022 May; 24(5):567-576. PubMed ID: 35201560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
    Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
    Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study.
    Mohammedi K; Woodward M; Hirakawa Y; Zoungas S; Colagiuri S; Hamet P; Harrap S; Poulter N; Matthews DR; Marre M; Chalmers J;
    Cardiovasc Diabetol; 2016 Sep; 15(1):129. PubMed ID: 27590190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiation of SGLT2 Inhibitors and the Risk of Lower Extremity Minor and Major Amputation in Patients with Type 2 Diabetes and Peripheral Arterial Disease: A Health Claims Data Analysis.
    Rodionov RN; Peters F; Marschall U; L'Hoest H; Jarzebska N; Behrendt CA
    Eur J Vasc Endovasc Surg; 2021 Dec; 62(6):981-990. PubMed ID: 34782230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up and down waves of glycemic control and lower-extremity amputation in diabetes.
    Caruso P; Scappaticcio L; Maiorino MI; Esposito K; Giugliano D
    Cardiovasc Diabetol; 2021 Jul; 20(1):135. PubMed ID: 34229673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.
    Badjatiya A; Merrill P; Buse JB; Goodman SG; Katona B; Iqbal N; Pagidipati NJ; Sattar N; Holman RR; Hernandez AF; Mentz RJ; Patel MR; Jones WS
    Circ Cardiovasc Interv; 2019 Dec; 12(12):e008018. PubMed ID: 31752517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study.
    Ding N; Kwak L; Ballew SH; Jaar B; Hoogeveen RC; Ballantyne CM; Sharrett AR; Folsom AR; Heiss G; Salameh M; Coresh J; Hirsch AT; Selvin E; Matsushita K
    Atherosclerosis; 2018 Jul; 274():86-93. PubMed ID: 29753232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical Therapy for Peripheral Artery Disease.
    Canonico ME; Hess CN; Rogers RK; Bonaca MP
    Curr Cardiol Rep; 2024 Jun; 26(6):651-659. PubMed ID: 38696099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: A narrative review.
    Liarakos AL; Tentolouris A; Kokkinos A; Eleftheriadou I; Tentolouris N
    J Diabetes Complications; 2023 Feb; 37(2):108390. PubMed ID: 36610322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
    Paul SK; Bhatt DL; Montvida O
    Eur Heart J; 2021 May; 42(18):1728-1738. PubMed ID: 33289789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging glucose-lowering therapies: a guide for cardiologists.
    Gulsin GS; Graham-Brown MPM; Davies MJ; McCann GP
    Heart; 2020 Jan; 106(1):18-23. PubMed ID: 31551292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review.
    Skeik N; Elejla SA; Sethi A; Manunga J; Mirza A
    Vasc Med; 2023 Feb; 28(1):62-76. PubMed ID: 36593757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Traditional and non-traditional risk factors for peripheral artery disease development/progression in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study.
    Cardoso CRL; Melo JV; Santos TRM; Leite NC; Salles GF
    Cardiovasc Diabetol; 2021 Feb; 20(1):54. PubMed ID: 33639945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.
    Mosenzon O; Del Prato S; Schechter M; Leiter LA; Ceriello A; DeFronzo RA; Raz I
    Cardiovasc Diabetol; 2021 Apr; 20(1):92. PubMed ID: 33910583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
    Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.